白介素-11治疗病毒感染所致血小板减少症的临床分析

目的分析霞绑人白介素-11（rhIL-11）治疗病毒感染所致血小板减少症的临床效果。方法选择2010年6月至2015年12月我院收治的病毒感染所致血小板减少症患者104例为研究对象．采用随机分数字表法分为观察组和对照组各52例，对照组采用常规疗法，观察组联合应用重组人白介素-11皮下注射。治疗10d后，比较两组的临床效果及血小板计数变化。结果观察组患者治疗总有效率92．31％明显高于对照组76．92％（x^2=4．727．P〈0．05）；血小板计数（158．42±45．23）叫硅高于对照纽（110．13±30．47）（t=6．385，P〈0．05）。结论重组人白介素-11可有效改善血小饭水平，提高病毒感染所致血小板减少症的治疗效果。

Objective To study the effect of recombinant human interleukin-ll （rhIL-11） clinical effect to reduce disease caused by virus infection and platelet therapy. Methods June 2010 to 2015 years 12 months in our hospital from virus infection induced platelet in patients with thrombocytopenia 104 cases as the rcsearch object, using randomized digital table were divided into ohservation group and control group, 52 cases in each group, the control group with conventional therapy, observation group were treated with recombinant human Bat Jie human interleukin-11 （rhIL-11 subcutaneously. Clinical effects and changes of platelet count were compared between the two groups after the treatment of 10 d. Results the total effective rate of the observation group was 92.31% higher than that of th.e control group 76.92% （x^2 =4. 727, P〈0.05）, platelet count （45.23±158.42） was significantly higher than that of the control group （110. 13±30.47） （t=6. 385, P〈0.05）. Conclusion recombinant human interleukin-ll can be effectively improve the level of platelet, improve the virus infection induced thrombocytopenia syndrome therapeutic effect.